Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-19T08:57:42.071Z Has data issue: false hasContentIssue false
  • English
  • Français

An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia

Published online by Cambridge University Press:  01 November 2007

G. Iohom ,
M. Ni Chonghaile ,
J. K. O’Brien ,
A. J. Cunningham ,
D. F. Fitzgerald  and
D. C. Shields
G. Iohom*
Affiliation:
Beaumont Hospital, Department of Anaesthesia and Intensive Care Medicine
M. Ni Chonghaile
Affiliation:
Beaumont Hospital, Department of Anaesthesia and Intensive Care Medicine
J. K. O’Brien
Affiliation:
Royal College of Surgeons in Ireland, SurGen Ltd
A. J. Cunningham
Affiliation:
Beaumont Hospital, Department of Anaesthesia and Intensive Care Medicine
D. F. Fitzgerald
Affiliation:
Royal College of Surgeons in Ireland, Department of Clinical Pharmacology, Dublin, Ireland
D. C. Shields
Affiliation:
Royal College of Surgeons in Ireland, SurGen Ltd
*
Correspondence to: Gabriella Iohom, C/o Department of Anaesthesia, Cork University Hospital, Cork, Ireland. E-mail: [email protected]; Tel: +353 214922566; Fax: +353 214546434
Get access

Abstract

Background and objective

The objectives of this study were, firstly, to characterize the inter-patient variability in the dose of propofol required to achieve a bispectral index <70 and ‘time to eye opening’ following propofol infusion and, secondly, to determine if the pharmacodynamic parameter ‘time to achieve bispectral index <70’ was influenced by genotype of the sex-linked drug receptor gene GABRE or if pharmacokinetic parameters such as clearance and ‘time to eye opening’ were influenced by the genotype of the metabolizing enzyme CYP2B6.

Methods

One hundred and fifty patients received a standardized anaesthetic. Apparent systemic clearance values were estimated. Correlation was sought between carriers of different CYP2B6 and GABRE genotypes and apparent systemic clearance, ‘time to achieve bispectral index <70’ and ‘time to eye opening’.

Results

Propofol induction/emergence characteristics varied, with slow recovery times in a subset of males. Time to loss of verbal contact and time to bispectral index <70 varied 6.6- and 4.3-fold, respectively. At emergence, there was a 15.5- to 111-fold variability in the measured time intervals. Clearance varied from 9.1 to 55.8 mL min−1 kg−1. The CYP2B6 C1459T (R487C) genotype frequencies were TT 1%, TC 22% and CC 67%. The three major haplotypes of CYP2B6 (R487C, K262R and Q172H variants) were not significantly associated with time to eye opening or clearance. Clearance was similar in 487C carriers and 487RR genotypes. There was no statistically significant correlation between the four major haplotypes of GABRE variants investigated ([mRNA358]G/T, 20118C/T, 20326C/T and 20502 A/T) and the observed anaesthesia induction time.

Conclusions

Great inter-patient variability exists in the dose of propofol required to achieve bispectral index <70, apparent systemic propofol clearance and time to eye opening. Common haplotypic differences at the CYP2B6 and GABRE genes do not appear to account for the majority of the observed inter-patient variability.

Keywords

ANAESTHESIA INTRAVENOUSPROPOFOLGABRE PROTEIN HUMANGENOTYPECYP2B6
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 24 , Issue 11 , November 2007 , pp. 912 - 919
Copyright
Copyright © European Society of Anaesthesiology 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Meyer, UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449–459.CrossRefGoogle ScholarPubMed
2.Ingelman-Sundberg, M. Functional consequences of polymorphism of xenobiotic metabolizing enzymes. Toxicol Lett 1998; 102–103: 155–160.CrossRefGoogle Scholar
3.Watson, KR, Shah, MV. Clinical comparison of ‘single agent’ anaesthesia with sevoflurane versus target controlled infusion of propofol. Br J Anaesth 2000; 85: 541–546.CrossRefGoogle ScholarPubMed
4.Patten, D, Foxon, GR, Martin, KF, Halliwell, RF. An electrophysiological study of the effects of propofol on native neuronal ligand-gated ion channels. Clin Exp Pharmacol Physiol 2001; 28: 451–458.CrossRefGoogle ScholarPubMed
5.Krasowki, MD, Jenkins, A, Flood, P, Kung, AY, Hopfinger, A, Harrison, NL. General anaesthetic potencies of a series of propofol analogs correlate with potency for potentiation of gamma-aminobutyric acid (GABA) current at the GABA(A) receptor but not with lipid solubility. J Pharmacol Exp Ther 2001; 297: 338–351.Google Scholar
6.Buggy, DJ, Nicol, B, Rowbotham, DJ, Lambert, DG. Effects of intravenous anaesthetic agents on glutamate release: a role for GABAA receptor-mediated inhibition. Anaesthesiology 2000; 92: 1067–1073.CrossRefGoogle ScholarPubMed
7.Davies, PA, Hanna, MC, Hales, TG, Kirkness, EF. Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. Nature 1997; 385: 820–823.CrossRefGoogle ScholarPubMed
8.Wilke, K, Gaul, R, Klauck, SM, Poustka, A. A gene in human chromosome band Xq28 (GABRE) defines a putative new subunit class of the GABA(A) neurotransmitter receptor. Genomics 1997; 45: 1–10.CrossRefGoogle Scholar
9.]Hachenberg, T. Perioperative management with short-acting intravenous anaesthetics. Anaesthesiol Reanim 2000; 25: 144–150.Google Scholar
10.Gan, TJ, Glass, PS, Sigl, J et al. . Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men. Anesthesiology 1999; 90: 1283–1287.CrossRefGoogle ScholarPubMed
11.Court, MH, Duan, SX, Hesse, LM, Venkatakrishnan, K, Greenblatt, DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001; 94: 110–119.CrossRefGoogle ScholarPubMed
12.Lang, T, Klein, K, Fischer, J et al. . Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399–415.CrossRefGoogle ScholarPubMed
13.Miksys, S, Lerman, C, Shields, PG, Mash, DC, Tyndale, RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003; 45: 122–132.CrossRefGoogle ScholarPubMed
14.Irizarry, K, Kustanovich, V, Li, C et al. . Genome-wide analysis of single nucleotide polymorphisms in human expressed sequences. Nat Genet 2000; 26: 233–236.CrossRefGoogle ScholarPubMed
15.Schaid, DJ, Rowland, CM, Tines, DE, Jacobson, RM, Poland, GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425–434. Epub 2001 Dec 27.CrossRefGoogle ScholarPubMed
16.Mander, AP. Haplotype analysis in population-based association studies. Stata J 2001; 1: 58–75.CrossRefGoogle Scholar
17.Sigl, JC, Chamoun, NG. An introduction to bispectral analysis for the electroencephalogram. J Clin Monit 1994; 10: 392–404.CrossRefGoogle ScholarPubMed
18.Glass, PSA, Bloom, M, Kearse, L, Rosow, C, Sebel, P, Manberg, P. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane and alfentanil in healthy volunteers. Anesthesiology 1997; 86: 836–847.CrossRefGoogle ScholarPubMed
19.Johansen, JW, Sebel, PS. Development and clinical application of electroencephalographic bispectrum monitoring. Anesthesiology 2000; 93: 1336–1344.CrossRefGoogle ScholarPubMed
20.Hoke, JF, Cunningham, F, James, MK, Muir, KT, Hoffman, WE. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. Pharmacology 1997; 281: 226–232.Google ScholarPubMed
21. Smith BE. Pharmacokinetics without calculus – an introduction. Int Anesthesiol Clin 1995; 33: 11–28.CrossRefGoogle Scholar
22.Morgan, DJ, Campbell, GA, Crankshaw, DP. Pharmacokinetics of propofol when given by intravenous infusion. Br J Clin Pharmacol 1990; 30: 144–148.CrossRefGoogle ScholarPubMed
23.Hesse, LM, He, P, Krishnaswamy, S et al. . Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225–238.CrossRefGoogle ScholarPubMed
24.Guitton, J, Buronfosse, T, Desage, M et al. . Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 1998; 80: 788–795.CrossRefGoogle ScholarPubMed
25.Hoymork, SC, Raeder, J, Grimsmo, B, Steen, PA. Bispectral index, predicted and measured drug levels of target-controlled infusions of remifentanil and propofol during laparoscopic cholecystectomy and emergence. Acta Anaesthesiol Scand 2000; 44: 1138–1144.CrossRefGoogle ScholarPubMed